APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Monoclonal Antibodies Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026

24 December 2025204 pages

Choose your research edition.

Industry ResearchTherapeutic Monoclonal Antibodies Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Monoclonal Antibodies Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Therapeutic Monoclonal Antibodies Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Therapeutic Monoclonal Antibodies Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Monoclonal Antibodies Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Monoclonal Antibodies Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Monoclonal Antibodies Drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck & Co, Novartis and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Therapeutic Monoclonal Antibodies Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Monoclonal Antibodies Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Monoclonal Antibodies Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Monoclonal Antibodies Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Monoclonal Antibodies Drug Segment by Company

AbbVie

Amgen

AstraZeneca

Bristol-Myers Squibb

Gilead Sciences

Johnson & Johnson

Merck & Co

Novartis

Roche

Innovent

Merck KGaA

Takeda

Seagen

Regeneron

Pfizer

Ono Pharmaceutical

Eli Lilly

Hengrui Medicine

Therapeutic Monoclonal Antibodies Drug Segment by Type

Chimeric Antibodies

Humanized Antibodies

Mouse-derived Antibodies

Therapeutic Monoclonal Antibodies Drug Segment by Application

Immune Diseases

Cancer

Other

Therapeutic Monoclonal Antibodies Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Therapeutic Monoclonal Antibodies Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Therapeutic Monoclonal Antibodies Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Monoclonal Antibodies Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Monoclonal Antibodies Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Monoclonal Antibodies Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Monoclonal Antibodies Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Monoclonal Antibodies Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Monoclonal Antibodies Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Monoclonal Antibodies Drug industry.

Chapter 3: Detailed analysis of Therapeutic Monoclonal Antibodies Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Therapeutic Monoclonal Antibodies Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Therapeutic Monoclonal Antibodies Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Monoclonal Antibodies Drug Industry Trends Table 2. Therapeutic Monoclonal Antibodies Drug Industry Drivers Table 3. Therapeutic Monoclonal Antibodies Drug Industry Opportunities and Challenges Table 4. Therapeutic Monoclonal Antibodies Drug Industry Restraints Table 5. Global Therapeutic Monoclonal Antibodies Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Monoclonal Antibodies Drug Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Company (2021-2026) Table 9. Global Therapeutic Monoclonal Antibodies Drug Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Therapeutic Monoclonal Antibodies Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Therapeutic Monoclonal Antibodies Drug Key Company Manufacturing Base & Headquarters Table 12. Global Therapeutic Monoclonal Antibodies Drug Company, Product Type & Application Table 13. Global Therapeutic Monoclonal Antibodies Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Therapeutic Monoclonal Antibodies Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Chimeric Antibodies Table 18. Significant Companies of Humanized Antibodies Table 19. Significant Companies of Mouse-derived Antibodies Table 20. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 21. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type (2021-2026) & (Tons) Table 22. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type (2027-2032) & (Tons) Table 23. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Type (2021-2026) Table 24. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Type (2027-2032) Table 25. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type (2021-2026) Table 29. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Immune Diseases Table 31. Significant Companies of Cancer Table 32. Significant Companies of Other Table 33. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 34. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application (2021-2026) & (Tons) Table 35. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application (2027-2032) & (Tons) Table 36. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Application (2021-2026) Table 37. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Application (2027-2032) Table 38. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application (2021-2026) Table 42. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application (2027-2032) Table 43. Global Therapeutic Monoclonal Antibodies Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 44. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026) & (Tons) Table 45. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2021-2026) Table 46. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2027-2032) & (Tons) Table 47. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2027-2032) Table 48. Global Therapeutic Monoclonal Antibodies Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Region (2021-2026) Table 51. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Region (2027-2032) Table 53. Global Therapeutic Monoclonal Antibodies Drug Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Therapeutic Monoclonal Antibodies Drug Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 58. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026) Table 59. Global Therapeutic Monoclonal Antibodies Drug Sales by Country (2027-2032) & (Tons) Table 60. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2027-2032) Table 61. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Therapeutic Monoclonal Antibodies Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Therapeutic Monoclonal Antibodies Drug Sales Value Market Share by Country (2027-2032) Table 65. AbbVie Company Information Table 66. AbbVie Business Overview Table 67. AbbVie Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 69. AbbVie Recent Development Table 70. Amgen Company Information Table 71. Amgen Business Overview Table 72. Amgen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 74. Amgen Recent Development Table 75. AstraZeneca Company Information Table 76. AstraZeneca Business Overview Table 77. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 79. AstraZeneca Recent Development Table 80. Bristol-Myers Squibb Company Information Table 81. Bristol-Myers Squibb Business Overview Table 82. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 84. Bristol-Myers Squibb Recent Development Table 85. Gilead Sciences Company Information Table 86. Gilead Sciences Business Overview Table 87. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 89. Gilead Sciences Recent Development Table 90. Johnson & Johnson Company Information Table 91. Johnson & Johnson Business Overview Table 92. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 94. Johnson & Johnson Recent Development Table 95. Merck & Co Company Information Table 96. Merck & Co Business Overview Table 97. Merck & Co Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 99. Merck & Co Recent Development Table 100. Novartis Company Information Table 101. Novartis Business Overview Table 102. Novartis Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 104. Novartis Recent Development Table 105. Roche Company Information Table 106. Roche Business Overview Table 107. Roche Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Roche Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 109. Roche Recent Development Table 110. Innovent Company Information Table 111. Innovent Business Overview Table 112. Innovent Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 114. Innovent Recent Development Table 115. Merck KGaA Company Information Table 116. Merck KGaA Business Overview Table 117. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 118. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 119. Merck KGaA Recent Development Table 120. Takeda Company Information Table 121. Takeda Business Overview Table 122. Takeda Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 123. Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 124. Takeda Recent Development Table 125. Seagen Company Information Table 126. Seagen Business Overview Table 127. Seagen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 128. Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 129. Seagen Recent Development Table 130. Regeneron Company Information Table 131. Regeneron Business Overview Table 132. Regeneron Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 133. Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 134. Regeneron Recent Development Table 135. Pfizer Company Information Table 136. Pfizer Business Overview Table 137. Pfizer Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 138. Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 139. Pfizer Recent Development Table 140. Ono Pharmaceutical Company Information Table 141. Ono Pharmaceutical Business Overview Table 142. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 143. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 144. Ono Pharmaceutical Recent Development Table 145. Eli Lilly Company Information Table 146. Eli Lilly Business Overview Table 147. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 148. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 149. Eli Lilly Recent Development Table 150. Hengrui Medicine Company Information Table 151. Hengrui Medicine Business Overview Table 152. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 153. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 154. Hengrui Medicine Recent Development Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. Therapeutic Monoclonal Antibodies Drug Distributors List Table 158. Therapeutic Monoclonal Antibodies Drug Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Therapeutic Monoclonal Antibodies Drug Product Image Figure 2. Global Therapeutic Monoclonal Antibodies Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Monoclonal Antibodies Drug Sales (2021-2032) & (Tons) Figure 5. Global Therapeutic Monoclonal Antibodies Drug Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Therapeutic Monoclonal Antibodies Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Chimeric Antibodies Image Figure 10. Humanized Antibodies Image Figure 11. Mouse-derived Antibodies Image Figure 12. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 13. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type (2021-2032) Figure 18. Immune Diseases Image Figure 19. Cancer Image Figure 20. Other Image Figure 21. Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 22. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application (2021-2032) Figure 27. Global Therapeutic Monoclonal Antibodies Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 28. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Therapeutic Monoclonal Antibodies Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Therapeutic Monoclonal Antibodies Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Therapeutic Monoclonal Antibodies Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Chimeric Antibodies
  • Humanized Antibodies
  • Mouse-derived Antibodies
Applications
  • Immune Diseases
  • Cancer
  • Other
Companies covered
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Roche
  • Innovent
  • Merck KGaA
  • Takeda
  • Seagen
  • Regeneron
  • Pfizer
  • Ono Pharmaceutical
  • Eli Lilly
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032)
  4. 1.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Therapeutic Monoclonal Antibodies Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Therapeutic Monoclonal Antibodies Drug Market Dynamics
  1. 2.1 Therapeutic Monoclonal Antibodies Drug Industry Trends
  2. 2.2 Therapeutic Monoclonal Antibodies Drug Industry Drivers
  3. 2.3 Therapeutic Monoclonal Antibodies Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Monoclonal Antibodies Drug Industry Restraints
3 Therapeutic Monoclonal Antibodies Drug Market by Company
  1. 3.1 Global Therapeutic Monoclonal Antibodies Drug Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Monoclonal Antibodies Drug Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Therapeutic Monoclonal Antibodies Drug Average Price by Company (2021-2026)
  5. 3.5 Global Therapeutic Monoclonal Antibodies Drug Company Ranking (2024-2026)
  6. 3.6 Global Therapeutic Monoclonal Antibodies Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Therapeutic Monoclonal Antibodies Drug Company Product Type and Application
  8. 3.8 Global Therapeutic Monoclonal Antibodies Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Therapeutic Monoclonal Antibodies Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Therapeutic Monoclonal Antibodies Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Therapeutic Monoclonal Antibodies Drug Market by Type
  1. 4.1 Therapeutic Monoclonal Antibodies Drug Type Introduction
  2. 4.1.1 Chimeric Antibodies
  3. 4.1.2 Humanized Antibodies
  4. 4.1.3 Mouse-derived Antibodies
  5. 4.2 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type
  6. 4.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type
  10. 4.3.1 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type (2021-2032)
5 Therapeutic Monoclonal Antibodies Drug Market by Application
  1. 5.1 Therapeutic Monoclonal Antibodies Drug Application Introduction
  2. 5.1.1 Immune Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application
  6. 5.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Therapeutic Monoclonal Antibodies Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application
  10. 5.3.1 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application (2021-2032)
6 Therapeutic Monoclonal Antibodies Drug Regional Sales and Value Analysis
  1. 6.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2027-2032)
  5. 6.3 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Therapeutic Monoclonal Antibodies Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032)
  12. 6.6.2 North America Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032)
  21. 6.9.2 South America Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Monoclonal Antibodies Drug Country-level Sales and Value Analysis
  1. 7.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Country (2027-2032)
  6. 7.4 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Therapeutic Monoclonal Antibodies Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Therapeutic Monoclonal Antibodies Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Therapeutic Monoclonal Antibodies Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Therapeutic Monoclonal Antibodies Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Merck & Co
  38. 8.7.1 Merck & Co Company Information
  39. 8.7.2 Merck & Co Business Overview
  40. 8.7.3 Merck & Co Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolio
  42. 8.7.5 Merck & Co Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Roche Therapeutic Monoclonal Antibodies Drug Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Innovent
  56. 8.10.1 Innovent Company Information
  57. 8.10.2 Innovent Business Overview
  58. 8.10.3 Innovent Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolio
  60. 8.10.5 Innovent Recent Developments
  61. 8.11 Merck KGaA
  62. 8.11.1 Merck KGaA Company Information
  63. 8.11.2 Merck KGaA Business Overview
  64. 8.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolio
  66. 8.11.5 Merck KGaA Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolio
  72. 8.12.5 Takeda Recent Developments
  73. 8.13 Seagen
  74. 8.13.1 Seagen Company Information
  75. 8.13.2 Seagen Business Overview
  76. 8.13.3 Seagen Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolio
  78. 8.13.5 Seagen Recent Developments
  79. 8.14 Regeneron
  80. 8.14.1 Regeneron Company Information
  81. 8.14.2 Regeneron Business Overview
  82. 8.14.3 Regeneron Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolio
  84. 8.14.5 Regeneron Recent Developments
  85. 8.15 Pfizer
  86. 8.15.1 Pfizer Company Information
  87. 8.15.2 Pfizer Business Overview
  88. 8.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolio
  90. 8.15.5 Pfizer Recent Developments
  91. 8.16 Ono Pharmaceutical
  92. 8.16.1 Ono Pharmaceutical Company Information
  93. 8.16.2 Ono Pharmaceutical Business Overview
  94. 8.16.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolio
  96. 8.16.5 Ono Pharmaceutical Recent Developments
  97. 8.17 Eli Lilly
  98. 8.17.1 Eli Lilly Company Information
  99. 8.17.2 Eli Lilly Business Overview
  100. 8.17.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolio
  102. 8.17.5 Eli Lilly Recent Developments
  103. 8.18 Hengrui Medicine
  104. 8.18.1 Hengrui Medicine Company Information
  105. 8.18.2 Hengrui Medicine Business Overview
  106. 8.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolio
  108. 8.18.5 Hengrui Medicine Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Therapeutic Monoclonal Antibodies Drug Value Chain Analysis
  2. 9.1.1 Therapeutic Monoclonal Antibodies Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Therapeutic Monoclonal Antibodies Drug Sales Mode & Process
  6. 9.2 Therapeutic Monoclonal Antibodies Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Therapeutic Monoclonal Antibodies Drug Distributors
  9. 9.2.3 Therapeutic Monoclonal Antibodies Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst